Eli Lilly plans $1 billion investment in India for global exports

US pharmaceutical giant Eli Lilly recently announced plans to invest $1 billion in India to establish a global export hub, marking one of the largest foreign direct investments by a drugmaker in the country as part of its strategy to expand international manufacturing capabilities. The investment will likely focus on establishing state-of-the-art manufacturing facilities in India, leveraging the country's growing pharmaceutical sector and skilled workforce. India has become an increasingly attractive destination for pharmaceutical manufacturing due to its cost advantages, robust regulatory framework, and established ecosystem for drug production. This move by Eli Lilly aligns with broader trends of pharmaceutical companies diversifying their manufacturing bases beyond traditional locations like the US and Europe to mitigate supply chain risks and tap into emerging markets. The $1 billion commitment represents a significant vote of confidence in India's pharmaceutical industry, which has already established itself as a major producer of generic drugs and increasingly complex pharmaceutical products.